Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Gabor Csanyi · AUGUSTA UNIVERSITY · 2022 · $385,000 — Project Summary Atherosclerosis, the main underlying cause of death worldwide, is characterized by chronic inflammation and accumulation of lipids in the arterial wall. Excessive lipid accumulation by macrophages (MΦs) and vascular smooth muscle cells (SMCs) plays a key role in the initiation and pr…
AJAY NMN RANA · JESSE BROWN VA MEDICAL CENTER · 2022 — Project Summary/Abstract: The main focus of research in our group is to understand the underlying molecular mechanisms of pancreatic and breast cancer pathogenesis. The overarching goal of our research is to investigate how the cellular pathways (i.e. circuits) are dysregulated and can lead to uncon…
Mats Ljungman · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2022 · $214,414 — ABSTRACT Chromosome rearrangements are common in cancers and typically occur early in carcinogenesis. They drive tumor development by altering the expression or function of oncogenes and tumor suppressor genes by copy number alterations, formation of oncogenic fusions or by alterations of DNA elemen…
Jiujiu Yu · UNIVERSITY OF NEBRASKA LINCOLN · 2022 · $348,975 — Obesity is a chronic progressive disease that leads to the development of heart disease, stroke, and type 2 diabetes, which are among the top ten leading causes of death in the United States. The initiation and progression of obesity-related diseases is strongly associated with chronic low-grade inf…
Yupeng Chen · UNIVERSITY OF CONNECTICUT STORRS · 2022 · $388,857 — Abstract More than 6 million Americans are living with Alzheimer’s disease (AD). AD is a neurodegenerative disease driven by abnormal accumulation of amyloid-β (Aβ) in the brain. Currently, we have very limited therapeutic approaches to treat AD. Aducanumab, designed to bind and inhibit toxic Aβ in…
Jacob Litke · CHIMERNA THERAPEUTICS INC. · 2022 · $256,158 — SUMMARY Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by inclusion bodies containing the TDP-43 protein in the cytoplasm of motor neurons. These inclusion bodies are caused by TDP- 43 aggregation, which is caused by pathways or mutations that cause TDP-43 to …
GABOR J TIGYI · UNIVERSITY OF MARYLAND BALTIMORE · 2022 · $296,245 — The US population at large, and particularly military personnel and first responders, are at risk of radiation exposure due to the explosion of a nuclear device, a nuclear reactor accident, and the threat of radiation terrorism. There is no radiation medical countermeasure (RCM) drug approved by th…
Sarah L Schlichte · UNIVERSITY OF NEBRASKA MEDICAL CENTER · 2021 · $19,119 — PROJECT SUMMARY/ABSTRACT The objective of this project is to identify the mechanisms by which the antioxidant MnTnBuOE-2-PyP5+ (BuOE) and its nanoformulation, nanoBuOE, decrease blood pressure. BuOE, a manganese porphyrin currently in clinical trials as a radioprotector in cancer patients, has prope…
Tasuku Kitada · STRAND THERAPEUTICS INC · 2021 · $399,725 — PROJECT SUMMARY Triple negative breast cancer (TNBC) has few treatments, and patients have a poor prognosis. Checkpoint inhibitors (e.g., anti-PD-1 antibodies) represent a promising new therapeutic strategy, and two recent clinical trials demonstrate that TNBC patients may benefit. However, only a f…
GREGORY C GIBSON · GEORGIA INSTITUTE OF TECHNOLOGY · 2021 · $172,745 — Project Summary Over the past decade, the NIDDK IBDGC (Inflammatory Bowel Disease Genetics Consortium) has generated extraordinary datasets in support of genetic analysis of the onset, progression, and therapeutic response to Crohn's disease and ulcerative colitis. This Ancillary project will comple…
Daniel John Siegwart · UT SOUTHWESTERN MEDICAL CENTER · 2021 · $357,210 — Project Summary Co-delivery of Cas9 mRNA and targeted sgRNA is a promising strategy to achieve CRISPR/Cas gene editing in vivo with improved safety. Although great advances have been made in the delivery of short RNAs (siRNA, miRNA), the ideal chemical and formulation composition is largely unknown …
Xiaowei Dong · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · 2021 · $365,544 — Project Summary/Abstract Bioavailability enhancement technologies for insoluble drugs represent incremental progress, but no breakthrough oral drug technologies have been identified in the past three decades. Lipid-based drug delivery systems (LBDDS) are considered as a well-established, very import…
Gaurav Sahay · OREGON STATE UNIVERSITY · 2021 · $183,227 — ABSTRACT Gene therapy strategies including augmentation, editing or knockdown, can lead to restoration of vision for patients suffering from inherited retinal degenerations (IRDs). Viral and non-viral vectors efficiently deliver genes through the subretinal route of administration, but this requires…
Chester Edward Markwalter · OPTIMEOS LIFE SCIENCES, INC. · 2021 · $255,351 — This application seeks to develop a long-acting depot formulation for antibodies, using the inverse Flash NanoPrecipitation (iFNP) platform being commercialized by Optimeos Life Sciences. Microparticle depot formulations have been tested for decades to provide sustained release. The therapeutic is t…
Prabhani Atukorale · UNIVERSITY OF MASSACHUSETTS AMHERST · 2021 · $194,524 — PROJECT SUMMARY Despite their transformative promise, traditional cancer vaccines have had poor clinical responses since vaccine-specific systemic T cells often cannot traffic to immunosuppressed “cold” tumors. Traditional vaccines generate only a lymph node-derived augmentation or “prime” of system…
Arif Yurdagul · LOUISIANA STATE UNIV HSC SHREVEPORT · 2021 · $249,000 — Atherosclerotic cardiovascular disease (CVD) is the leading cause of death in the industrialized world. Most atherosclerotic plaques are clinically silent; however, a subset can lead to myocardial infarction, stroke, or sudden death. Atheromas that are linked to clinical events are characterized by …
Amit Praful Khandhar · HDT BIO CORPORATION · 2021 · $399,285 — PROJECT SUMMARY/ABSTRACT Effective targeted treatments are needed to improve survival of patients with late stage ovarian and other solid tumor cancers of epithelial origin. Epithelial cancers are characterized by an overexpression of tumor tight junctions, specifically the cell adhesion protein des…
Yuchao Chen · WELLSIM BIOMEDICAL TECHNOLOGIES, INC. · 2021 · $197,500 — PROJECT SUMMARY / ABSTRACT Extracellular vesicles (EVs) are small lipid bilayer particles secreted by most cell types, which encapsulates biomolecules including lipids, proteins, and nucleic acids from parent cells. Profiling of EV-derived biomarkers provides a promising approach for early diagnoses…
CYRUS R SAFINYA · UNIVERSITY OF CALIFORNIA SANTA BARBARA · 2021 · $295,265 — Project Summary/Abstract The current level of research activity involving gene therapy with either synthetic vectors (carriers) or engineered viruses is unprecedented. Liposomes are the most widely studied nonviral carriers worldwide for nucleic acid (NA) and drug delivery applications. Cationic lip…
Jinjun Shi · BRIGHAM AND WOMEN'S HOSPITAL · 2021 · $585,626 — ABSTRACT The use of RNA technologies to specifically target genetic alterations in tumor cells has shown great potential of becoming a novel therapy modality for cancer treatment. Nevertheless, systemic delivery of RNA agents such as messenger RNA (mRNA) to tumor cells in vivo commonly faces multipl…